ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

Spend billions of dollars to cover anti-obesity drugs under Medicare and Medicaid, or deny more than 7 million people access ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...